BioReference Laboratories has purchased U.S. Ariosa, Roche's prenatal testing business. U.S. Ariosa offers a noninvasive prenatal screening test called Harmony Prenatal that has been used by more than 1.5 million women.
BioReference offers a similar test, ClariTest Core, through its specialty health division, GenPath, it said; U.S. Ariosa's Harmony Prenatal will round out the company's prenatal screening portfolio.
